New Data at ASCO Highlights Utility of MRD Monitoring

Natera, Inc, presented four abstracts at ASCO about its assay, Signatera, and its ability to track circulating tumor DNA for residual disase monitoring in colorectal cancer and in hepatocellular carcinoma. 

"We are looking forward to sharing new clinical data at this year's ASCO meeting, which demonstrates our progress towards establishing Signatera as an effective tool for residual disease detection," said Alexey Aleshin, M.D., M.B.A., Natera's Senior Medical Director for Oncology. "The data from these studies support our efforts to set a new standard in residual disease monitoring in patients with colorectal cancer, while expanding ctDNA testing applications to guide optimal treatment options for a broader range of cancer patients."

Read more on P&T Community.


Theme picker